Introduction
Germ cell cancer is the most common malignancy in men aged 15-35 years; 5% of the malignant germ cell tumors are of extragonadal origin [1] . An extragonadal germ cell tumor (EGGCT) is by definition a germ cell neoplasm displaying one of the histologies associated with gonadal origin, but located outside of the gonads. This specific clinical entity was first described in the 19th century [2, 3] . Histological, serological and cytogenetic characteristics of EGGCTs are similar to those of primary testicular germ cell tumors, but major differences in clinical behavior suggest that gonadal and extragonadal tumors are biologically different (Table 1 ). In particular, this is true of primary mediastinal EGGCTs and tumors originating in the sacrococcygeal or pineal region; in contrast, tumors arising in the retroperitoneum are more often associated with premalignant lesions in one of the testes and behave clinically in a manner very similar to that of the primary testis counterpart. Also male patients with carcinoma of unknown primary (CUP syndrome) with undifferentiated histology and typical germ cell tumor serum markers, as well as presentation in the midline structures, belong to the group of EGGCT. However, in practice it may be difficult to distinguish extragonadal tumors from metastatic tumors where the primary testis lesion has regressed, e.g. in some cases a scar is found in the testis probably representing a 'burn-out' or 'autoinfarcted' primary [4] . Furthermore, it is unclear whether the presence of a carcinoma in situ or intraepithelial germ cell neoplasia represents a primary tumor lesion resulting in metastatic deposits e.g. in the mediastinum or retroperitoneum, or whether this testicular lesion represents a general premalignant or malignant change of germ cells at any location distributed in the body, leading to an extragonadal malignant tumor.
Biology and genetics
It is generally accepted that EGGCTs follow the same principles of development from primordial germ cells as primary gonadal germ cell tumors. While their migration from the yolk sac-endoterm to the genital ridge which occurs in the midline, aberrant midline migration might enable primordial germ cells to lodge in the site where extragonadal germ cell tumors are commonly found. Accordingly, the cytogenetic finding of one or multiple copies of the short arm of chromosome 12p with the loss of the long arm of chromosome 12 is seen in nearly all germ cell cancers of primary gonadal and extragonadal origin [5, 6] . This concept, however, is challenged by findings from serial sections in human embryos and murine embryos [7, 8] , which failed to find any evidence of misplaced germ cells outside of the gonads. Furthermore, it has been recently shown that ectopically placed primordial germ cells detected in sections of murine embryos undergo apoptosis [9] . Chaganti et al. [10] compared the clonal cytogenetic changes in a group of primary extragonadal tumors with a group of primary gonadal tumors, with the hypothesis that if these tumors truly represented de novo transformations of primordial germ cells in a nongonadal environment, then their genetic and cytogenetic profile may be different from those of gonadal germ cell tumors. Although the two groups differed significantly in the pattern of differentiation, neither specific chromosomal aberrations, including increased 12p copy number, nor the incidence of recurring break points were significantly different between the two groups. These finding led to an alternative suggestion that some form of reverse migration of occult carcinoma in situ lesions in the testis could occur; Table 1 . Clinical and biological features of extragonadal germ cell tumors with respect to gonadal germ cell tumors [11] AFP, α-fetoprotein; β-HCG, β human chorionic gonadotropin. according to this hypothesis extragonadal tumors would also be of gonadal origin [10] . The potential development of malignant gonadal and extragonadal germ cell tumors is described in Figure 1 , which has been adapted from Chaganti et al. [6] . However, neither of these two series explain the striking predominance of malignancy in male EGGCTs in comparison with females who predominantly have EGGCTs and germ cell tumors of the ovaries that are benign [11] . TIN (or carcinoma in situ, cis) cells are regarded as the precursors of all male germ cell tumors; however, it is unclear how cis cells undergo the molecular changes leading to high DNA content and the typical chromosomal aberrations seen in this cancer. The molecular changes associated with the development of germ cell tumors are still not clearly understood. However, it is clear from the universal cytogenetic finding of increased 12p copy number that this chromosomal change is a key event. Candidate driver genes are currently in the process of being identified using the techniques of molecular profiling, CGH analysis, etc. Of particular interest is an amplification of the proximal 12p11.2-12 region which includes the genes ras-k2, SOX5 and JAW1, as well as cycline CCND2 mapped to the 12p13 region, which could be the best candidate for the 12p3 gene in normal testicular genesis and malignant germ cell development [12] and growth. The most likely target cell for transformation during germ cell development may be a cell with replicated chromosomes that expresses wild-type p53, harbors DNA breaks and which may be prone to apoptosis. Such a stage is represented by the zytogene-pachytene spermatocyte at which a 'recombination checkpoint' appears to operate which can provide an apoptotic trigger in the presence of an unresolved DNA double-strand break. This stage is temporally the longest phase during spermatogenesis with the cell cycle machinery halted to allow the recombinational events to complete. It also contains replicated DNA, and based on murine data, wild-type p53 protein is temporally expressed at this stage. According to this model Figure 1 . Genetics and biology of male germ cell (GC) tumors [7] . A diagrammatic representation of male GC development during a normal life span and the proposed model of GC transformation. The key genetic events that underlie normal male GC fate and embryonal development are shown with respect to their spatial and temporal relationships. Germ cell tumor development is depicted in the context of normal GC biology. aberrant chromatid exchange events associated with crossing over the zytogene-pachytene may lead to increased 12p copy number and overexpression of cyclin D2. Such a cell may escape a recombination checkpoint-associated apoptotic response through the oncogenic effect of cycline D2, leading to aberrant re-initiation of cell cycle and genomic instability. In germ cells that have, under follicle-stimulating hormone (FSH) stimulation, re-entered the cell cycle after cycline D2 activation, downstream events such as a loss of tumor suppressor genes induced by genomic instability could lead to neoplastic progression. Candidate suppressor genes are Rb1, DCC and NME (for a review see Chaganti and Houldsworth [6] ). An overview of this hypothetical development of germ cell tumors is given in Figure 1 .
Except for a few described cases of germ cell tumors diagnosed in fathers and twins, there is no evidence for familiar inheritance. However, there is a clear association between EGGCT and Klinefelter's syndrome and a possible association with Down's and Li-Fraumeni syndromes. Klinefelter's syndrome is a male genetic disorder characterized by the 47,XXY karyotype, small and soft testis, sterility, eunuchoid habitus, gynecomasty, high levels of FSH, a 20-fold increased risk for breast cancer and an increased risk of EGGCT primary gonadal germ cell tumors. These tumors mainly occur in young children, with a peak in incidence at 10 years, before that of gonadal germ cell tumors. It is, however, unclear whether the development of germ cell tumors in patients with Klinefelter's syndrome is the result of primary genetic abnormality, errors during embryonic development or abnormal hormonal milieu priming premalignant tumor cells into malignant tumor growth.
Histopathology
Like their counterparts of gonadal origin, EGGCTs occur in several characteristic histological patterns that reflect the stages of normal embryonic and fetal development with seminomatous ('germinoma/dysgerminoma') and nonseminomatous germ cell tumors including endodermal sinus tumor, yolk sac tumor, embryonal carcinoma, choriocarcinoma and mature or immature teratoma. Histopathological pattern and tumor marker expression of α-fetoprotein (AFP), β human chorionic gonadotropin (β-HCG) and alkaline phosphatase, as well as LDH, follow the same pattern as primary gonadal germ cell tumors.
Whereas the proportion of seminomatous and nonseminomatous germ cell tumors in primary gonadal tumors is more or less equal, in EGGCTs seminomatous histology is seen in only 20-24% of EGGCTs. In a cumulated series of 635 cases with EGGCTs collected from 11 different institutions, there were 104 and 524 patients with seminomatous and nonseminomatous extragonadal germ cell tumors, respectively [13] . There is no predominance of either histology in patients with primary mediastinal or primary retroperitoneal seminomatous or nonseminomatous extragonadal germ cell tumors.
Clinical presentation
The most common localization of EGGCTs is in the mediastinum and retroperitoneum. Beyond this the tumors can arise in the pineal region, sacrococcygeal region and also in the prostate, vagina, orbita, liver and gastrointestinal tract ( Table 2) . Because of the rarity of the other localizations of EGGCTs, this chapter only reports on primary mediastinal and retroperitoneal EGGCTs.
The most conclusive data regarding clinical presentation and treatment results derive from a recent meta-analysis representing the largest published series of EGGCTs with 635 patients [13] . Patients with mediastinal EGGCT had in particular dyspnea (25%), chest pain (23%) and cough (17%) at initial presentation, followed by fever (13%), weight loss (11%), vena cava occlusion syndrome and fatigue/weakness (6%). Less frequent than expected was chest pain, cervical nodes (2%), hemoptysis, hoarseness and dysphagea (1% each). In patients with a tumor in a primary retroperitoneal location, the lead symptoms are abdominal (29%) and back pain (14%), followed by weight loss (9%), fever (8%), vena caval or other thrombosis (9%), palpable abdominal tumor (6%), cervical nodes (4%), scrotal edema (5%), gynecomastia and dysphagea (3%).
The pattern of age distribution for seminomatous and nonseminomatous EGGCTs is comparable with gonadal tumors, with a median age of onset of 33, 41, 28 and 30 years for mediastinal seminoma, retroperitoneal seminoma, mediastinal nonseminoma and retroperitoneal nonseminoma, respectively. Half of the patients with extragonadal seminomatous tumors have elevated β-HCG and/or LDH; in extragonadal nonseminomatous tumors there seems to be a different pattern between mediastinal and retroperitoneal EGGCTs with 74% of the mediastinal tumors presenting with elevated AFP and (Tables 3 and 4 ). The size of the mediastinal tumor is nearly double that of nonseminomatous tumors, 9 cm (range 7-30) in comparison with 5 cm (range 1-20) in mediastinal seminoma, whereas the size of retroperitoneal EGGCTs is comparable in both histologies. Metastases are less frequent at diagnosis with seminomatous EGGCTs (40% of patients) compared with nonseminomatous EGGCTs (50% for mediastinal and 76% for retroperitoneal nonseminomatous EGGCTs). The pattern of metastases outside of the primary tumor location varies depending on the location of the primary tumor and its histology; mediastinal seminomas mostly have metastatic deposits in the cervical lymph nodes whereas mediastinal nonseminoma is associated in particular with lung metastases in 27% of patients. Retroperitoneal seminoma is found in the retroperitoneal primary tumor lymph node metastases in 26%, mediastinal lymph nodes in 12% and cervical lymph nodes in 6%, whereas retroperitoneal nonseminomatous tumors have a high frequency of lung metastases (49%), abdominal (34%), or cervical lymph nodes (18%) and liver metastases (25%). The proportion of patients with two or more metastatic sites follows the patients with primary gonadal origin and typical pattern of poor prognosis germ cell
Diagnosis
Since EGGCTs are not clinically evident with a primary gonadal tumor, in virtually all patients the diagnosis is led by the symptoms induced by the growing mediastinal or retroperitoneal tumor mass. Fine needle cytology or histology through percutaneous or mediastinoscopic biopsy reveals 
Testicular biopsy
A testis primary is excluded by sonographic investigation of the testis. Several reports have described the presence of a testicular intraepithelial neoplasia (TIN) or microscopic scar in the testis of patients with EGGCT. The largest biopsy series is reported in the above-mentioned meta-analysis [13] with 71 patients (11% of the whole series) undergoing biopsy. Three per cent showed a sertoli cell only syndrome, 31% athrophic or fibrotic testis and in 9% TIN was evident with a higher proportion in primary retroperitoneal EGGCTs than in mediastinal tumors. Further to this observation, 12 of 524 nonseminomatous EGGCTs and four of 104 seminomatous EGGCTs developed metachronous testicular tumors, mostly seminoma, after a median follow-up of 6 years [14] . Although according to this data the standard incidence ratio (SIR) is greatly increased (SIR 62) in comparison with patients with primary testis tumors resulting in a 10% cumulative risk at 10 years after diagnosis of EGGCT, these metachronous testicular tumors are highly curable due to the limited stage at presentation and their mostly seminomatous histology. A routine bilateral testicular biopsy of patients with EGGCT is therefore not justified.
Prognosis
Primary mediastinal and retroperitoneal extragonadal seminomatous germ cell tumors have an equivalent prognosis as their primary gonadal counterpart, with a 5-year survival of 88% (Table 5 and Figure 2 ) in a meta-analysis of 104 patients [15] . The same parameters which identified patients with gonadal seminomatous tumors as having a good or intermediate prognosis, including levels of HCG or LDH, presence of nonpulmonary visceral metastases or primary mediastinal tumor, also predict the individual prognosis in seminomatous tumor of primary extragonadal origin.
Nonseminomatous EGGCTs have a worse prognosis than seminomatous EGGCTs with a 5-year survival rate of 62% for retroperitoneal and 45% for mediastinal nonseminomatous EGGCTs (Figure 2) . Accordingly, the complete response (CR) rate including partial response with marker normalization is lower than in seminomatous EGGCT with 68% for retroperitoneal and 64% for mediastinal primary, and the relapse rate is much higher at 50% and 52%, respectively (Table 5) . Also, the analysis according to the IGCCCG classification shows that patients with primary retroperitoneal EGGCT and good/intermediate prognostic features belong to the category of poor prognosis, with a 5-year survival of only 59% and 61% [13] . These data clearly indicate that not only do mediastinal EGGCTs have a poor prognosis and should be treated accordingly, but that retroperitoneal EGGCTs also belong to the poor prognosis group even if they fulfil the IGCCCG criteria of good or intermediate prognosis. Since the response and survival data are based on a meta-analysis of the largest number of patients ever reported in an EGGCT trial, Table 5 . Treatment outcome in a cumulative series of 635 patients with EGGCT [13] CR, complete response, OS, overall survival; PR, partial response; PFS, progression-free survival. Figure 2 . Calculated overall survival rates of (A) 104 nonseminomatous EGGCT patients and (B) 524 nonseminomatous extragonadal germ cell tumor (EGGCT) patients according to the primary tumor location [13] .
the results probably reflect the true situation better than single center studies; however, most studies reported results which are relatively consistent with these data [16] [17] [18] [19] [20] [21] [22] . The conclusions from the data are as follows:
• 
The role of high-dose chemotherapy
No prospective studies have investigated the role of high-dose chemotherapy in first-line treatment of extragonadal tumors.
In a meta-analysis of 524 patients with nonseminomatous germ cell tumors, 59 patients (13%) were treated with highdose chemotherapy [13] . No specific data of this subgroup, which would be the largest series of high-dose chemotherapy in this specific disease type, is yet available. However, in the univariate analysis for prognostic factors high-dose chemotherapy obviously was not a significant prognostic factor for improved survival. Sixty-four patients out of another series of 235 patients with mainly poor prognostic criteria (IGCCCG) treated with initial sequential high-dose chemotherapy with cisplatinum plus intermediate high-dose etoposide and ifosfamide plus stem cell rescue had extragonadal germ cell tumors, with a 5-year survival reported to be higher than with standard dose platinum-based combination chemotherapy [23] . This has resulted in the inclusion of these patients with primary mediastinal or poor prognosis retroperitoneal germ cell tumors into the current European Organisation for Research and Treatment of Cancer (EORTC) study, which is comparing four cycles of standard dose PEB with one cycle of standard etoposide, ifosfamide, cisplatin (VIP) followed by three cycles of high-dose VIP plus stem cell rescue. The result of this study will probably highlight more precisely the role of high-dose chemotherapy for this specific patient population.
The role of radiation
As reported in the meta-analysis by Bokemeyer et al. [13] the relapse rate in patients with bulky extragonadal seminoma treated with radiation alone is relatively high, in accordance with the retrospective analysis of other earlier studies. Therefore, radiation therapy, as part of the treatment strategy of advanced seminoma and in particular extragonadal seminoma, has been abandoned. However, for salvage treatment in cases of otherwise untreatable disease, e.g. definitive progression under chemotherapy, radiotherapy is the treatment of choice and will be actively used-at least for sometime-in the majority of patients. Salvage radiotherapy is therefore an important measure for some patients with otherwise refractory disease suffering from locoregional problems, such as superior vena cava obstruction, bronchus obstruction, cases of residual disease after salvage surgery, as well as CNS metastases.
The role of secondary surgery
Due to poor prognosis in many patients with retroperitoneal EGGCTs and the specific localization of primary mediastinal EGGCT, surgery is a very important part of the treatment strategy. In the above-mentioned series [13] secondary surgery after chemotherapy has been performed in about 50% of extragonadal seminomatous tumors revealing necrosis in only 92% of the resected patients; 49% of patients with mediastinal EGGCT underwent secondary resection of residual tumor mass in the mediastinum resulting in viable germ cell tumor in 34% and non-germ cell tumor elements in 1.4%, major teratoma in 26% and necrotic tissue in 37%. In nonseminomatous retroperitoneal EGGCT, 45% of the patients underwent secondary surgery, mainly of the retroperitoneal residuum; viable undifferentiated tumor was found in 25%, major teratoma in 16% and necrotic tissue in 59% of patients. These data are in accordance with data of a recent series from Memorial Sloan-Kettering Cancer Center with 32 patients presenting with mediastinal EGGCT [24] and clearly indicate that secondary surgery is an integral part of the treatment strategy in patients with EGGCT and is mandatory in the case of residual mass, which is true for about 50% of the patient population.
Salvage chemotherapy
The outcome of patients relapsing after primary chemotherapy for EGGCTs is very poor and probably worse than patients with primary gonadal nonseminomatous testicular cancer and poor prognostic features. From a collected series of 142 patients treated prospectively in 11 European and American centers in an era when cisplatinum was widely used, only 19% of patients were long-term disease-free after standard or high-dose salvage chemotherapy followed by additional surgical resection of residual tumors in some patients [25] . Primary mediastinal location and cisplatinum-refractory patients have been identified as independent factors predicting a negative outcome with standard or high-dose salvage chemotherapy. In this series, 28% of 79 patients with mediastinal and 41% of patients with retroperitoneal extragonadal germ cell tumors received high-dose chemotherapy at relapse. The median survival time was 15 months for patients treated with high-dose chemotherapy and 11 months for patients treated with standard-dose salvage chemotherapy protocols;
although the survival curves are in favor of high-dose chemotherapy, there is no statistically significant difference between both groups in terms of median and long-term survival. These data are in accordance to results from individual small series where long-term survival in patients relapsing after chemotherapy of a mediastinal germ cell tumor have only rarely been observed. In conclusion, currently there is no role for high-dose chemotherapy as salvage treatment at the time of relapse after initial remission, or in cases of primary cisplatinum resistance, in patients with mediastinal and probably also retroperitoneal extragonadal germ cell tumors. The data from a prospective randomized trial of the European Group for Blood and Marrow Transplantation comparing standard cisplatinum-based salvage chemotherapy with highdose salvage chemotherapy also including patients with extragonadal germ cell tumors are eagerly awaited [26] .
Second malignancies
The cumulative risk of development of metachronous testicular cancer 10 years after diagnosis of EGGCT is about 10% according to the results from a meta-analysis by Hartmann et al. [14] . The rate of metachronous testicular cancer is higher among patients with nonseminomatous EGGCTs and retroperitoneal EGGCTs (14%), than in patients with seminomatous EGGCTs (1.4%) or seminomatous mediastinal EGGCTs (6.2%). This represents an increased standard incidence ratio (SIR), derived from the incidence of metachronous testicular cancer in the primary gonadal testis cancer population of 62 (95% confidence interval 36-99). However, most cases of metachronous testicular cancer in these patients are of seminomatous histology, which is also true in patients with primary nonseminomatous EGGCT, and is therefore associated with a good prognosis.
The risk of developing secondary non-germ cell solid tumors is not increased with an incidence of 2% after a median follow-up of 55 months [27] . However, there is an increased risk, in patients with mediastinal EGGCT, of developing acute megacaryoblastic leukemia or myelodysplasia with abnormal megacaryocytes (2% of patients). With a standard incidence ratio of 250 in comparison with a normal age matched general population [28, 29] . The median time to onset of hematological neoplasia is 6 months (range 0-47) and the median survival after diagnosis of the hematological malignancy is short at 5-6 months, due to the poor biology of these leukemias, despite autologous or allogenic bone marrow transplantation. The secondary leukemias are clearly different cytogenetically from leukemias induced by alkylating agents or topoisomerase II inhibitors with typical cytogenetic findings of a germ cell tumor, in particular the presence of an isochromosome 12p. Interestingly, leukemias only appear in patients with primary nonseminomatous mediastinal EGGCTs, not in patients with primary retroperitoneal EGGCTs.
Conclusions
Extragonadal germ cell tumors are a very interesting tumor entity with specific biological and clinical characteristics. The prognosis is excellent in cases of seminomatous histology independent of the localization of the EGGCT in either the mediastinum or retroperitoneum. Unfortunately the majority of patients (80%) have nonseminomatous EGGCTs and thereby have poor prognosis which is independent of the primary location of the nonseminomatous EGGCT. Standard cisplatinum-based chemotherapy plus additional secondary surgery in half of all patients is the basis of the treatment strategy. Salvage chemotherapy including high-dose chemotherapy has no significant impact on long-term survival; however, this must be prospectively investigated.
Due to the poor prognosis and several potential clinical problems associated with the disease and treatment, these patients should be treated primarily in specialized centers.
